Melbourne, Australia–(BUSINESS WIRE)–Propanc Biopharma, Inc. (OTCQB: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients with recurrent and metastatic cancer, today announced that a notice of acceptance was received from the United States Patent and Trademark Office (USPTO) for claims regarding a new method of treating cancer stem cells (CSC). The authorized US patent protects the exclusive claims of capture methods and uses of pancreatic proenzymes to treat cancer by specifically targeting and eradicating CSCs.
CSCs make up only a small fraction of a tumor’s cell population and can lie dormant for periods of time, bypassing standard treatment approaches like radiation and chemotherapy that target dividing cells. Therefore, a priority to improve treatment and reduce the risk of relapse is to develop a strategy that targets the eradication of SCC, while leaving healthy cells alone. This continues to be a specific area of interest as the company’s lead product candidate, PRP, moves into first-in-man study for the treatment of patients with advanced-stage solid tumors.
The authorized patent, citing the new CCS processing method, is currently one of 4 patent families, consisting of 65 patents in force or pending in jurisdictions worldwide. It is the first cleared by the USPTO covering a method of minimizing the progression of cancer in a patient by administering a therapeutically effective amount of two proenzymes, trypsinogen and chymotrypsinogen, thereby preventing metastatic cancer in the patient by targeting and eradicating CSCs from solid tumors.
“The granting of this patent by the USPTO is an important step for our intellectual property portfolio in the world’s largest healthcare market and confirms that our claims cover a new therapeutic approach for the treatment and prevention of metastatic cancer. , which is the leading cause of patient death for the sick,” said James Nathanielsz, Chief Executive Officer of Propanc. “It is particularly important to continue to develop and grow our intellectual property portfolio, as we move forward on the drug development path. Further patent applications are expected and we are excited about the growth and commercial potential of our portfolio to create significant long-term shareholder value.
A point of difference from other CSC therapies is the ability of the company’s technology to differentiate cancer stem cells to exhibit normal behavior, so that they become benign and die naturally, rather than directly killing. the CSCs. This means that CSCs are selectively targeted based on the proteins they express, which healthy cells do not, leaving healthy stem cells alone. Therefore, based on scientific evidence to date, PRP is considered less toxic compared to standard treatment approaches. PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from the bovine pancreas administered by intravenous injection. A synergistic ratio of 1:6 inhibits the growth of most tumor cells. Examples include kidney, ovarian, breast, brain, prostate, colorectal, lung, liver, uterine, and skin cancers.
About Propanc Biopharma, Inc.
Propanc Biopharma, Inc. (the “Company”) is developing a novel approach to prevent recurrence and metastasis of solid tumors using pancreatic proenzymes that target and eradicate cancer stem cells in patients with pancreatic, ovary and colorectal. For more information, please visit www.propanc.com.
The company’s new proenzyme therapy is based on the science that enzymes stimulate biological reactions in the body, specifically enzymes secreted by the pancreas. These pancreatic enzymes may represent the body’s main defense against cancer.
To view the Company’s “Mechanism of Action” video on its lead cancer product candidate, PRP, please click on the following link: http://www.propanc.com/news-media/video
All statements other than statements of historical fact contained in this press release are “forward-looking statements”, which can often, but not always, be identified by the use of words such as “may”, “could”, ” will”, “probably result”, “should”, “should”, “estimate”, “plan”, “project”, “plan”, “intend”, “expect”, “anticipate” , “believe”, “seek”, “continue”, “target” or the negative of these terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements. These factors include uncertainties about the Company’s ability to continue as a going concern in the absence of new debt or equity financing; the Company’s current dependence on significant debt financing which it is unable to repay in cash; the Company’s ability to successfully address material weaknesses in its internal controls; the Company’s ability to achieve research and development milestones as planned and within proposed budgets; the Company’s ability to control costs; the Company’s ability to obtain adequate new financing on reasonable terms; the Company’s ability to successfully initiate and complete clinical trials and its ability to successfully develop PRP, its lead product candidate; the Company’s ability to obtain and maintain patent protection; the Company’s ability to recruit employees and directors with accounting and financial expertise; the Company’s dependence on third parties for services; the Company’s dependence on key management; the impact of government regulations, including FDA regulations; the impact of any future litigation; the availability of capital; changes in economic conditions, competition; and other risks, including, but not limited to, those described in the Company’s periodic reports filed with the Securities and Exchange Commission and available on its website at http://www.sec.gov. These forward-looking statements speak only as of the date hereof, and the Company disclaims any obligation to update these statements except as required by law.